The U.S. Food and Drug Administration has approved AbbVie's (NYSE: ABBV) tavapadon, marketed as JUVMO, for the treatment of Parkinson's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE